JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dillon, G. H.
Right arrow Articles by Hamilton, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dillon, G. H.
Right arrow Articles by Hamilton, B. J.

[4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline] is a novel ligand to the picrotoxin site on GABAA receptors, and decreases single-channel open probability

GH Dillon, WB Im, JF Pregenzer, DB Carter and BJ Hamilton

CNS Diseases Research, Upjohn Company, Kalamazoo, Michigan.

U-93631,[4-dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline], represents a GABAA receptor ligand of novel chemical structure, and has been shown to induce a rapid, time-dependent decay of GABA-induced whole-cell Cl- currents in recombinant GABAA receptors (Dillon et al., 1993). In this study, we found that the drug competitively inhibited [35S]t-butylbicyclophosphorothionate binding to the picrotoxin site on a cloned GABAA receptor, alpha 1 beta 2 gamma 2, and preempted the action of picrotoxin and [35S]t-butylbicyclophosphorothionate on GABA- induced Cl- currents. We further examined the effect of U-93631 on GABA- induced single channel openings in outside-out patches. U-93631 (5 microM) showed no effect on single channel conductance, the duration of channel open states or the short closed state, but increased the duration of the long closed state and its relative contribution to total closed time. In addition, closings of very long duration (> 500 msec), albeit rare, occurred more frequently in the presence of U- 93631. Thus, the probability of single channel openings decreased from 0.12 +/- 0.02 to 0.04 +/- 0.01 in the presence of U-93631 (5 microM). These properties of U-93631 are analogous to those of picrotoxin and [35S]t-butylbicyclophosphorothionate reported in earlier studies with native neurons. We conclude that U-93631 at least shares overlapping binding domains with picrotoxin and [35S]t- butylbicyclophosphorothionate, and the ability to stabilize the GABAA receptor/Cl- channel complex in an inactivated state(s).(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 272, Issue 2, pp. 597-603, 02/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
R.-Q. Huang, C. L. Bell-Horner, M. I. Dibas, D. F. Covey, J. A. Drewe, and G. H. Dillon
Pentylenetetrazole-Induced Inhibition of Recombinant gamma -Aminobutyric Acid Type A (GABAA) Receptors: Mechanism and Site of Action
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 986 - 995.
[Abstract] [Full Text]


Home page
J. Neurophysiol.Home page
R.-Q. Huang and G. H. Dillon
Effect of Extracellular pH on GABA-Activated Current in Rat Recombinant Receptors and Thin Hypothalamic Slices
J Neurophysiol, September 1, 1999; 82(3): 1233 - 1243.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
F. Gao and S. M. Wu
Characterization of Spontaneous Inhibitory Synaptic Currents in Salamander Retinal Ganglion Cells
J Neurophysiol, October 1, 1998; 80(4): 1752 - 1764.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics.